ER 50891 (quarterhydrate)
ER 50891 quarterhydrate is a RARα antagonist. ER 50891 can significantly antagonize the inhibitory effect of all-trans retinoic acid (ATRA) on the total cell metabolic activity and proliferation of MC3T3-E1 preosteoblasts. ER 50891 rescues ATRA-inhibited osteocalcin (OCN) expression and extracellular matrix mineralization, and suppresses alkaline phosphatase (ALP) activity synergistically. ER 50891 can be used for the study of osteoporosis related to ATRA-induced inhibition of osteoblastogenesis[1].
Product Specifications
UNSPSC
12352211
Target
RAR/RXR
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/er-50891-quarterhydrate.html
Purity
99.86
Solubility
DMSO : 25 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C(O)C1=CC=C(C2=CC=C(C3=NC4=C(C(C)C)C=CC=C4C(C5=CC=CC=C5)=C3)N2)C=C1.[1/4].O
Molecular Formula
C29H24N2O2.1/4H20
Molecular Weight
437.02
References & Citations
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Cytokeratin, HMW (AE-3), CF647 conjugate, 0.1mg/mL
Histone H1 (AE-4), CF568 conjugate, 0.1mg/mL
Squamous Cell Carcinoma Antigen 1 (CPTC-SERPINB3-2), CF488A conjugate, 0.1mg/mL
CD8 (C8/468 + C8/144B), CF488A conjugate, 0.1mg/mL
